Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H12N4O2 |
| Molecular Weight | 232.2386 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC=C(N1CCC2=CC=NC=C2)[N+]([O-])=O
InChI
InChIKey=ARYPMCPJIWUCIP-UHFFFAOYSA-N
InChI=1S/C11H12N4O2/c1-9-13-8-11(15(16)17)14(9)7-4-10-2-5-12-6-3-10/h2-3,5-6,8H,4,7H2,1H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/343312
Sources: https://www.ncbi.nlm.nih.gov/pubmed/343312
Panidazole, an antiprotozoal agent that was studied in patients for the treatment of intestinal amoebiasis and vaginal trichomoniasis. However, information about the further development of this drug is not available.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The mutagenic action of nitroimidazoles. II. Tinidazole, ipronidazole, panidazole and ornidazole. | 1977-04 |
|
| Laboratory evaluation of panidazole (1-(2'-( -pyridyl) ethyl-2-methyl)-5-nitroimidazole), a new amoebicide. | 1972-06 |
|
| 1-(2-(gamma-pyridyl)ethyl)-2-methyl-5-nitro-imidazole (panidazole), a new amoebicide. | 1970-09-26 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/343312
panidazole between 1.0 and 2.0 g per day for six days
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
08AHL2YV5K
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
SUB09604MIG
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105336
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
13752-33-5
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
C66302
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
72080
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
2963
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
C016029
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
237-334-3
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
DTXSID50160209
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY | |||
|
100000082767
Created by
admin on Mon Mar 31 18:20:29 GMT 2025 , Edited by admin on Mon Mar 31 18:20:29 GMT 2025
|
PRIMARY |
ACTIVE MOIETY